Table 2 Incidence of adverse events in the two groups
Adverse Events | Group 1 (n = 19) | Group 2 (n = 40) | ||
|---|---|---|---|---|
Any | Grade ≥ 3 | Any | Grade ≥ 3 | |
Anaemia, n (%) | 2 (10.5) | 0 | 5 (12.5) | 2 (5) |
Leukopenia, n (%) | 6 (31.6) | 1(5.3) | 14 (35.0) | 0 |
Neutropenia, n (%) | 1 (5.3) | 0 | 3 (7.5) | 1(2.5) |
Thrombocytopenia, n (%) | 1 (5.3) | 0 | 3 (7.5) | 0 |
Increased aspartate/alanine aminotransferase, n (%) | 1 (5.3) | 0 | 2 (5) | 0 |
Decreased estimated glomerular filtration rate, n (%) | 0 | 0 | 1 (2.5) | 0 |
Anorexia, n (%) | 5 (26.3) | 0 | 9 (22.5) | 0 |
Diarrhoea, n (%) | 0 | 0 | 2 (5) | 0 |
Constipation, n (%) | 1 (5.3) | 0 | 3 (7.5) | 0 |
Reactive cutaneous capillary endothelial proliferation, n (%) | 4 (21.1) | 0 | 0 | 0 |
Hypothyroidism, n (%) | 2 (10.5) | 0 | 1 (2.5) | 0 |